Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT07681505
Starting soon Observational

Analysis of the Role of the Microbiota in Diverticular Disease

NCT07681505 · tracked via the Priya Life Science Spain tracker
Sponsor
Hospital of Navarra
Phase
Observational
Started
2027-06-01
Last updated
2026-09-02

Condition(s) studied

Diverticular Disease of ColonAcute DiverticulitisGut Microbiota

Study summary

A single-center, prospective observational cohort study conducted at the University Hospital of Navarra. The primary objective is to expand knowledge of diverticular disease and its pathological variants, as well as the influence of the microbiota in our environment, both clinically and molecularly; to describe the clinical and pathological characteristics of patients with diverticulosis and acute diverticulitis; to analyze any differences in the microbiota; and to identify the risk factors and groups associated with diverticular disease in order to establish the best strategies for prevention and treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 18 or older. * Signing of the informed consent form. * Assignment to one of the study groups mentioned above. Exclusion Criteria: * An episode of acute diverticulitis located in the right colon or transverse colon. * Antibiotic treatment within the six weeks prior to the episode (except for antibiotics started in the emergency department or within 24 hours prior to sample collection). * Mechanical bowel preparation within the three weeks prior to sample collection. * Diagnosis of colorectal cancer. * Diagnosis of inflammatory bowel disease. * Failure to sign the informed consent form.

Primary outcome measure(s)

  • To investigate the microbiota influences the development of diverticulosis — From the diagnosis until two years
    To investigate whether the microbiota influences the development of diverticulosis and a first episode of acute diverticulitis.

Trial sites (1)

FacilityCityRegionStatus
Hospital Universitario de Navarra Pamplona Navarre

More Hospital of Navarra trials in Spain

Application of Indocyanine Green Tracer in D2 Lymphadenectomy of Locally Advanced Gastric Cancer Starting soon

Other trials for the same condition

SMASH: Study to Evaluate the Clinical Efficacy of an Extensively Hydrolysed Infant Formula With Synbiotics and a Human Milk Oligosaccharide (HMO) in Infants With Cow's Milk Protein Allergy (CMPA) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07681505 on ClinicalTrials.gov ↗ ← All trials in Spain